Aduhelm, an anti-amyloid monoclonal antibody approved for Alzheimer's, failed to show meaningful clinical benefit despite targeting the amyloid hypothesis, suggesting that amyloid reduction alone is insufficient for cognitive protection.
factualpending
Speaker
Dr. David PerlmutterEvidence Quote
“Aduhelm uh fiasco, where a drug was created that uh was designed to target beta amyloid and how that turned out not to be meaningful drug”
Source
Oral Bacteria And Your Health - with Dr. Mark Burhenne | The Empowering Neurologist EP. 162— DavidPerlmutterMDCreated: 8/12/2026, 6:27:27 PM
Your notes
Loading notes...